NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19

Translate to Spanish or other 102 languages!

Image for illustration purposes only.

Mega Doctor News

- Advertisement -

Newswise – One week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC)— along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation on ivermectin, making it an option for use in COVID-19. 

This new designation upgraded the status of ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation. 

By no longer recommending against ivermectin use, doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA emergency use approval. 

- Advertisement -

“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” noted Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.” 

In its ivermectin recommendations update, the NIH also indicated they will continue to review additional trials as they are released. “We are encouraged that the NIH has moved off of its August 27 recommendation against the use of ivermectin for COVID-19,” continued Kory. “That recommendation was made just as the numerous compelling studies for ivermectin were starting to roll in. New studies are still coming in, and as they are received and reviewed, it is our hope that the NIH’s recommendation for the use of ivermectin will be the strongest recommendation for its use as possible.” 

Current meta-analyses of studies of ivermectin from around the world show a compelling trend towards the drug’s potent benefits against SARS-CoV-2. Ivermectin, developed in 1975, led to the eradication of a “pandemic” of parasitic diseases across multiple continents and earned the 2015 Nobel Prize for Physiology or Medicine for its discoverers, Dr. William Campbell and Dr. Ōmura Satoshi. 

In related news, the manuscript written by the FLCCC has been accepted for publication, following a rigorous peer review, in Frontiers in Pharmacology.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral to Host Webinar on Coping with Holiday Stress, Dec 3

The holiday season is often described as the most wonderful time of the year. However, for many people, it can also bring feelings of stress, sadness, anxiety and loneliness.

New Book Gives Families Language to Discuss Epilepsy

Each November, National Epilepsy Awareness Month invites people to learn how to recognize and respond to a seizure. 

Study Links Higher Vitamin D Levels to Better Sleep

Higher vitamin D levels were associated with longer and less interrupted sleep in middle-aged and older adults, in a study led by researchers at the Johns Hopkins Bloomberg School of Public Health in collaboration with scientists at the National Institute on Aging.

Caring for Others Starts With Caring for Yourself

November is National Family Caregivers Month. Whether you're caring for an aging parent or a loved one with a chronic illness, caregiving can be stressful. It's important to remember taking care of yourself is just as important.
- Advertisement -